Articles On Neuren Pharmaceuticals (ASX:NEU)

Highlights: ASX healthcare stocks edge ahead of the broader market with key innovations and updates PolyNovo (ASX:PNV) unveils promising NovoSorb developments in diabetes research Neuren (ASX:NEU), Microba (ASX:MAP), and Ram...

ASX health stocks up 2.1% over past week, while the broader market is up 2%  President Donald Trump signs executive order to cut US drug prices under ‘most favored nation’ policy PolyNovo has a breakthrough with its NovoSorb technology in...

The S&P/ASX 200 Index (ASX: XJO) snatched a victory from the jaws of defeat this Wednesday. After sinking into red territory for most of today's session, the ASX 200 recovered in the nick of time t...

Highlights Core Lithium’s stock experiences strongest daily movement since a previous multi-year high Finniss Project study outlines lowered operational and capital costs with increased production ASX 200 continues upward tr...

US President Donald Trump has signed an executive order aimed at reducing drug costs for Americans, by up to 80% immediately. The move immediately hit Australia's pharmaceutical industry as 3 ASX pharmaceutical stocks crashed up to 10% s...

 Investors with a short position in wound care house Polynovo face a nervous wait Oz drug stocks partly recover after swooning yesterday on Trump drug-pricing edict Wellnex Life rediscovers its sales mojo, while Elinixol Wellness goes to t...

Highlights Mineral Resources (MIN) observed increased market activity amid global trade updates. Elixir Energy (EXR) advanced following a new strategic direction led by recent leadership changes. Biotechnology stocks, includ...

Some of the ASX’s best-known pharmaceutical companies – including Neuren, Telix and Clarity – have reported losses on Monday, after Donald Trump announced a plan to cut prescriptions drug prices by up to 80% via an executive order. The i...

Highlights Energy and mining stocks helped lift the ASX200 on Monday. Trade optimism between the US and China boosted commodity sentiment. Macquarie and South32 were notable movers in corporate news. The Australian share market ki...

Highlights Mineral Resources Ltd (ASX:MIN) drew attention amid governance-related news and stock price action South32 Ltd (ASX:S32) reported executive leadership transition affecting market sentiment Neuren Pharmaceuticals L...

Highlights ASX pharmaceutical stocks saw notable declines following U.S. policy comments. Trump's proposal aims to drastically cut U.S. prescription drug prices. Companies with U.S.-based pipelines or approvals felt the immediate mark...

Highlights  ASX200 sees modest gains amid global optimism  Energy and mining stocks climb on stronger commodity prices  Goodman Group and BHP lead early momentum  The Australian share market opened the week on a positive note, wit...

The ASX200 has been up 0.32% at around 8,257 points. Mineral Resources Ltd (ASX:MIN) has been well-watched on HotCopper today, after rising 5.65% despite news that superannuation fund HESTA has sold its remaining stake in the company, ci...

Highlights  ASX200 rises on positive US-China trade sentiment  BHP and Santos among top performing resource stocks  Copper discovery, iron ore jump support mining sector  The Australian sharemarket opened on a positive note, buoye...

It was a positive end to the trading week for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares this Friday. A third day of gains in a row for the ASX 200 saw it close at 8,231.2 points today. T...

Highlights: ANZ Group provides insights into first-half earnings, with a focus on capital stability and strategic de-risking. S&P/ASX 200 remains flat at noon with fluctuations across various sectors. Unusual volume obse...

Highlights Neuren Pharmaceuticals (NEU) reported strong sales figures in the biotech sector. Pointerra (3DP) advanced in the tech space with a US Army contract. Locksley Resources (LKY) moved forward with drilling approvals...

The ASX200 has been up 0.2% at around 8,195 points. Neuren Pharmaceuticals (ASX:NEU) has been the most watched on HotCopper so far today, after reporting Q1 FY25 sales of its DAYBUE product increased by 11% to US$84.6 million over the co...

Neuren says the number of patients discontinuing its Rett syndrome drug has fallen by two-thirds over the last year LTR Pharma launches a secondary program for swallowing disorders Telix targets throat – and other – cancers Neuren Pharmac...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13...

Highlights Several ASX 200 directors made notable share purchases, including from Neuren Pharmaceuticals, BHP, GQG Partners, and Viva Energy Group. BHP's directors acquired additional shares amid market fluctuations, while GQG's...

Highlights Australian sharemarket closes higher following positive global trade sentiment Technology sector leads with strong gains, while Neuren Pharmaceuticals and DroneShield advance Broad-based gains seen across sectors,...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin ASX200 futures are pointing to a positive start, up 18 points, but US markets finish...

Neuren Pharmaceuticals (ASX:NEU) and its US partner Acadia Pharmaceuticals have been blitzing it with its Rett syndrome drug Daybue (formerly trofinetide), which has exceeded the expectations of two years ago when the drug was approved in t...

Highlights: Australian sharemarket finished higher, supported by broader strength across Asian equities and US futures Technology sector led the gains, advancing the most among all sectors Neuren Pharmaceuticals and DroneShi...

Highlights Technology and materials sectors led the ASX gains amid stronger iron ore and gold prices Elixir Energy lifted as leadership transitioned to former Strike Energy executive EBR Systems declined following FDA approv...

Highlights: The ASX 200 Index closed higher as most sectors ended the session in positive territory. Tech, materials, and healthcare shares were among the top-performing sectors. Neuren Pharmaceuticals topped the leaderboard...

It was a flying start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. After a rough end to last week, investors came back from the weekend with a spring in their steps. By th...

ASX climbs 1.34pc with 10/11 sectors in the green Base metal prices recover as USD falls Gold continues strong performance, remaining near all-time highs   It’s certainly a calmer start to the week for the markets today. Strong numbers fr...

Good Afternoon and welcome to HotCopper’s Market Close for Monday 14th of April, I’m Jonathon Davidson. The local bourse traded green on Monday with IT in the lead up 2.6% led by Wall Street, followed by Materials up 2.1%, led by higher...

Highlights Mining and banking sectors lifted the ASX, with broad market strength across major indices Technology and real estate stocks added further support amid easing trade tensions Neuren Pharmaceuticals surged after pos...

Highlights Mining, financials, and energy sectors lead upward momentum Major banks and resource companies post solid intraday advances DroneShield and Neuren Pharmaceuticals record strong intraday surges The Australian...

Highlights: ASX rises strongly during midday trade amid easing trade tensions between the US and China Neuren Pharmaceuticals jumps after Phase 3 trial confirmation for rare neurological condition Grand Gulf Energy leads sma...

Highlights Miners and banks fuel broad ASX gains Tech and gold stocks shine on global cues Neuren Pharmaceuticals soars after FDA milestone The Australian sharemarket kicked off the week on a strong note, with major gains led by m...

Highlights  ASX rises on global tech optimism and commodity gains  Neuren Pharmaceuticals leads with double-digit surge  Strong moves seen in tech, mining, and defense sectors  Australian shares climbed on Monday as optimism aroun...

Neuren Pharma (ASX:NEU) has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome (PMS) – the first ever to be conducted. Listen to the HotCopper podcast for in-depth discussions and insi...

The ASX has been up 1% higher at 7,721 points. Invictus Energy (ASX:IVZ) has been among the most watched on HotCopper forums after the company confirmed Musuma-1 as the first high-impact exploration well to be drilled outside the Mukuyu...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street's lead and is pushing higher. At the time of writing, the benchmark index is up 1.1% to 7,728.6 points. Four ASX shares that are rising more than most today are listed below. He...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are starting the week with an almighty bang. In morning trade, the ASX 200 biotech stock is up a massive 18% to $10.83. Why is this ASX 200 stock jumping? Investors have been bidding the pharmace...

Highlights Major U.S. indexes, including the S&P 500 and Nasdaq, experience significant overnight gains. Australian pharmaceutical stocks fluctuate after recent tariff updates. Investors watch closely for companies that don’t foll...

The US market took off, in a fashion I’ve not seen in my career, after Trump sent this message on his social media platform: “Authorised a 90 day PAUSE, and a substantially lowered Reciprocal Tariff during this period, of 10%, also effectiv...

Highlights: Short interest surged across uranium developers and producers amid sector-wide declines. James Hardie recorded a sharp uptick in short interest after a controversial acquisition. Limited short covering observed,...

Highlights: Neuren Pharmaceuticals reports a price-to-earnings ratio below the broader market. The company's earnings have shown a decline, influencing its valuation. Market expectations indicate continued financial challeng...

Highlights: ASX 200 moves higher with technology and real estate stocks gaining traction. Light & Wonder and Megaport stand out with notable price increases. Some resource stocks experience declines, including Liontown a...

Some investors contend Clinuvel’s mountain of $200 million of cash is excessive and amounts to a ‘lazy’ balance sheet The company argues the cash buffer protects it against unexpected adversities and – in any event – every cent will be nee...

Highlights: ASX200 sees fluctuations as various sectors experience gains and declines. Energy and Consumer Staples lead with positive performances, while Information Technology faces setbacks. Notable stock movements inclu...

The ASX200 closed down 0.38% at 7,969 points. Energy was the best performing sector, up1%, followed by Staples, up 0.4%, and Materials, up 0.33%. Real Estate was the biggest loser, down 2.2%, followed, IT, down 2%, and Discretionary,...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and dropping into the red. At the time of writing, the benchmark index is down 0.6% to 7,953.4 points. Four ASX shares that are not letting that hold them back are lis...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

A couple of ASX 200 biotech stocks are in the spotlight today after releasing big news. However, while one is pushing higher, the other has dropped into the red. Let's see what is happening: Mesoblast Ltd (ASX: MSB) The Mesoblast share pri...